Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| , Complete if Known | | | | | |
|------------------------|----------------------------|--|--|--|--|
| Application Number 109 | RCPYCLASSIGNed2 0 DEC 2004 | | | | |
| | | | | | |
| First Named Inventor | Andrew 20/518817 | | | | |
| Art Unit | Not Known | | | | |
| Examiner Name | Not Known | | | | |
| Attorney Docket Number | 100727-1P US | | | | |

| | U. S. PATENT DOCUMENTS | | | | | |
|-----------------------|------------------------|--|---|--|---|--|
| Examiner Initials* | Cite No. | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | |
| | | Number-Kind Code ^{2 (# Isnown)} | | | Figures Appear | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| - ' | | US- | | | | |
| | t — | US- | . · · · · · · · · · · · · · · · · · · · | | | |
| | | US- | | | | |
| | † — | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | ··· | | | |
| | 1 | U\$- | | | | |
| _ | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | † | US- | | | | |
| - | † | US- | | | | |
| | † | US- | | | | |
| | 1 | US- | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----|----|--------------------------------|--|---|----------------------------|----------|
| Examiner Initials* | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ | |
| 1M | B1 | | ternational Search Report | | | or neievant igores reposit | |
| W | B2 | wo | 03020278 A1 | March 13, 2003 | Novartis Pharma GMBH | | |
| M | В3 | wo | 0232879 A1 | April 25, 2002 | Naeja Pharmaceutical Inc. | | <u> </u> |
| W | B4 | wo | 9709315 A1 | March 13, 1997 | Signal Pharmaceuticals, Inc. | | _ |
| M | B5 | wo | 0055125 | Sept. 21, 2000 | Axys Pharmaceuticals, Inc. | | <u> </u> |

| Examiner Signature | V. Bul | ersulvamajan | Date Considered | 9/16/ | 05 |
|-----------------------|--------|--------------|--------------------|-------|----|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.